Search

Meet Andrew Kung, MSK’s new Chair of the Department of Pediatrics.

… Thursday, September 15, 2016 Summary Andrew Kung has a long history of caring for children with cancer. He now brings his talents to MSK as the new Chair of the Department of Pediatrics . Andrew Kung understands the first-day-of-school excitement that many of his patients went through this month — because

The surgical removal of the ovaries has been widely adopted as a cancer-risk-reducing strategy for women with either BRCA1 or BRCA2 mutations. A new multicenter study led by researchers at Memorial Sloan Kettering Cancer Center is the first prospective examination of the impact of this procedure in which BRCA2 mutation carriers were analyzed separately from BRCA1 mutation carriers.

… Monday, February 11, 2008 The surgical removal of the ovaries has been widely adopted as a cancer-risk-reducing strategy for women with either BRCA1 or BRCA2 mutations. A new multicenter study led by researchers at Memorial Sloan Kettering Cancer Center (MSKCC) is the first prospective examination of

Memorial Sloan Kettering Cancer Center (MSK) today announced the largest single donation in its nearly 150-year history, a $400 million gift from Kenneth C. Griffin, Founder and Chief Executive Officer of Citadel and Founder of Griffin Catalyst, and David Geffen, Founder of The David Geffen Foundation. It will serve as the cornerstone of MSK’s foundation for the future and will be instrumental in extending the power and potential of cancer care and treatment to people across New York and around the world as MSK continues to advance cutting-edge research and new cancer treatments.

… Tuesday, December 12, 2023 Donation To Enhance Care, Treatment, and Outcomes for People Across New York and Around the World Memorial Sloan Kettering Cancer Center (MSK) today announced the largest single donation in its nearly 150-year history, a $400 million gift from Kenneth C. Griffin, Founder and

Given the current pandemic, every time a healthcare provider asks a patient to come in for an appointment, they’re making a mental calculation of the risk and benefit. Utilizing telemedicine has allowed providers at Memorial Sloan Kettering (MSK) to keep patients safely sheltered at home, while continuing to provide their necessary care.

… Thursday, May 7, 2020 Going through treatment for cancer is almost like having a fulltime job. Patients can have multiple appointments, and it is not uncommon for some patients to have three or more visits a week. Given the current pandemic, every time a healthcare provider asks a patient to come in

Breast pathologist Edi Brogi explains what patients should know about breast cancer diagnosis, second opinions, and promising new developments in treating some of the most aggressive forms of the disease.

… Tuesday, November 14, 2017 Summary Edi Brogi, a breast pathologist, explains what patients should know about breast cancer diagnosis, second opinions, and promising new developments in treating some of the most aggressive forms of the disease. A breast cancer diagnosis often starts when a change is found

Meet Emily Herzlin, who teaches mindfulness and meditation at Memorial Sloan Kettering.

… Wednesday, October 25, 2017 Summary Emily Herzlin, who teaches meditation through MSK’s Integrative Medicine Service , offers insight into how it can help people with cancer, survivors, and caregivers. Can the simple acts of being still, noticing your thoughts, and focusing on your breath really be transformative

Nick Kroll, Seth Meyers, Amy Schumer, John Mulaney, and special guests hosted the one-night-only event, taking the stage to outwit blood cancers and raising a record-breaking $2.3 million to fuel Memorial Sloan Kettering Cancer Center’s mission of ending cancer for life.

… Tuesday, May 20, 2025 Comedy vs Cancer, the official comedy benefit show for blood cancer research at Memorial Sloan Kettering Cancer Center (MSK), returned to Jazz at Lincoln Center’s Frederick P. Rose Hall. The sold-out, one-night-only event raised over $2.3   million to support lifesaving blood cancer

The FDA has approved the drug trastuzumab deruxtecan for the treatment of advanced non-small cell lung cancer driven by mutant HER2. An MSK-led study published in September 2021 contributed to the drug's approval.

… Friday, August 12, 2022 On August 11, 2022, the U.S. Food and Drug Administration (FDA) approved the drug trastuzumab deruxtecan (also known as T-DXd or Enhertu®) for the treatment of advanced non-small cell lung cancer (NSCLC) driven by mutant HER2. Trastuzumab deruxtecan was previously approved for

Daniela Molena, MD, Director, Esophageal Surgery Program, talks on expanding organ preservation surgery in esophageal cancer and the quest to pinpoint the elusive sentinel node in these patients.

… Wednesday, March 6, 2019 VIDEO | 03:47 Expanding Organ Preservation Surgery in Esophageal Cancer Daniela Molena, MD, Director, Esophageal Surgery Program, talks on expanding organ preservation surgery in esophageal cancer and the quest to pinpoint the elusive sentinel node in these patients. Video Details

At the 2016 American Association for Cancer Research (AACR) conference, there were clear signs that cancer treatment is evolving from a slash-and-burn method to a more precisely targeted, intelligent approach.

… Wednesday, April 20, 2016 Summary Genomic sequencing of tumors is allowing cancer researchers to tailor treatments to patients in a way that was previously not possible, allowing a more targeted, personalized approach to cancer care. Increasingly, the focus of research is on finding the right combination